William Thomas, MD
Interventional Cardiology · Tucson, AZNPI 1891773024
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,944 of the $55,544 with a category attached, or 75.5%. Boehringer Ingelheim accounts for 66.5% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $16,587 and has fallen 97.3% since, to $450 in 2025.
Across 441 payments — averaging $125.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$37K
- Lilly USA, LLC$6K
- Edwards Lifesciences$4K
- Abbott$2K
- Boston Scientific$2K
- Novartis$700
- plus $3K from 28 others
Across 1 payment — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$15K
What the payments were for
- Speaking & faculty fees$41,94476%
- Travel & lodging$1,5823%
- Food & beverage$11,75521%
- Education$2630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 39 | $36,945 |
| Lilly USA, LLC | 7 | $6,219 |
| Edwards Lifesciences | 97 | $4,268 |
| Abbott | 30 | $2,451 |
| Boston Scientific | 34 | $1,796 |
| Novartis | 72 | $700 |
| Medtronic(2 entities) | 7 | $436 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $341 |
| Johnson & Johnson(2 entities) | 19 | $332 |
| Astellas Pharma US Inc | 9 | $265 |
| Amgen | 17 | $242 |
| Pfizer | 13 | $196 |
| Cardiva Medical, Inc. | 23 | $190 |
| Cardiac Dimensions, Inc. | 1 | $115 |
| Sanofi-aventis U.S. LLC | 7 | $113 |
| Biotronik Inc. | 5 | $107 |
| Philips North America LLC | 1 | $94 |
| Bard Peripheral Vascular, Inc. | 1 | $93 |
| AstraZeneca | 6 | $86 |
| Esperion Therapeutics, Inc. | 4 | $71 |
| Regeneron Healthcare Solutions, Inc. | 4 | $63 |
| Chiesi USA, Inc. | 2 | $51 |
| Amarin Pharma, Inc. | 4 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Kestra Medical Technology Services, Inc. | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Caris MPI, Inc. | 1 | $33 |
| Lundbeck LLC | 2 | $33 |
| Abiomed | 1 | $30 |
| Merck | 2 | $30 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,544 in reported general payments places this provider in the 85th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 268 | $338,881 |
| JardianceEmpagliflozin | 89 | $123,537 |
| XareltoRivaroxaban | 81 | $98,797 |
| Repatha SureclickEvolocumab | 119 | $82,230 |
| EntrestoSacubitril/Valsartan | 29 | $32,850 |
| BrilintaTicagrelor | 16 | $16,478 |
| Rosuvastatin Calcium | 606 | $8,688 |
| Metoprolol Succinate | 621 | $6,723 |
| ClopidogrelClopidogrel Bisulfate | 362 | $4,603 |
| Ezetimibe | 146 | $4,306 |
| Atorvastatin Calcium | 360 | $4,177 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 20 | $2,542 |
| Amlodipine Besylate | 330 | $2,410 |
| Carvedilol | 221 | $1,778 |
| Potassium Chloride | 120 | $1,701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $196 | $338,881268 claims |
| Boehringer IngelheimJardiance | $36,945 | $123,53789 claims |
| Johnson & JohnsonXarelto | $332 | $98,79781 claims |
| NovartisEntresto | $700 | $32,85029 claims |
| AstraZenecaBrilinta | $86 | $16,47816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Tucson
- Thomas WaggonerTucson$617K
- Kapildeo LotunTucson$365K
- Neil GheewalaTucson$141K
- Dexter de LeonTucson$74K
- Ranjith ShettyTucson$50K
- Santiago RamirezTucson$45K
- Sulaiman RathoreTucson$32K
- Michel CorbanTucson$27K
- Sundeep ShenoyTucson$24K
- Paul SorajjaPhoenix$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.